GIST

THE-630 will no longer be developed for patients with GIST after patients treated at the 27 mg dose experienced dose-limiting toxicities.

In an interview with Targeted Oncology, Jonathan C. Trent, MD, PhD, discussed primary and offshoot analysis data from the INTRIGUE study of patients with GIST.

Experts say results from a phase 1 study of olverembatinib in patients with succinate dehydrogenase-deficient gastrointestinal stromal tumor were encouraging and warrant further research.

In a phase 1/2 study, THE-630 is displaying preliminary anti-tumor activity and tolerable safety in patients with advanced gastrointestinal stromal tumors.

In an interview with Targeted Oncology, Alexander Helfand, MD, discussed the treatment of GIST in the second-line setting, as well as later lines, including the available options, guideline recommendations, and ongoing research.

Edwin Choy, MD, discusses the evolution of treatment for gastrointestinal stromal tumors, including surgery and targeted therapy.

In an interview, Edwin Choy, MD, discussed the treatment landscape of GIST and recent changes to NCCN guidelines.

Ripretinib will be evaluated in a phase 3 trial for patients with gastrointestinal stromal tumor after being added to the NCCN guidelines and receiving 2 breakthrough therapy designations from the FDA.

Ripretinib now has 2 breakthrough therapy designations from the FDA and has been added to the NCCN guidelines for gastrointestinal stromal tumor.

Neeta Somaiah, MD, discusses her presentation given at the Inaugural Miami Cancer Institute Precision Medicine Oncology Symposium.

In an interview with Targeted Oncology, Neeta Somaiah, MD, explained how targeted therapies have started to re-shape the treatment of sarcomas and the potential role of immunotherapy in the future.

According to experts, results from the INTRIGUE study have shown the utility of ctDNA next-generation sequencing for patients with advanced gastrointestinal stromal tumor.

INTRIGUE study results show that patients with gastrointestinal stromal tumor who harbor certain KIT mutations have significantly improved responses and survival with ripretinib treatment.

Targeted therapy with tyrosine kinase inhibitors is necessary after surgery for patients with metastatic gastrointestinal stromal tumors with residual disease requiring resection to prevent disease recurrence.

There remains a need for biomarkers of primary gastrointestinal stromal tumor subclones to characterize invasion or metastasis, according to Jonathan A. Fletcher, MD.

In the Chinese population of the global INVICTUS trial, ripretinib was found to have a manageable safety profile and produced a good response rate.

Full results from the phase 3 INVICTUS trial show stable progression-free survival advantage and improved overall survival with ripretinib in patients with an advanced gastrointestinal stromal tumor.

Compared with sunitinib, second-line treatment with ripretinib did not improve progression-free survival in patients with gastrointestinal stromal tumor.

Pimitespib, a heat shock protein 90 inhibitor doubled the progression-free survival and prolonged the overall survival compared with placebo in patients with advanced gastrointestinal stromal tumor that is refractory to imatinib, sunitinib, and regorafenib, according to results from the phase 3 CHAPTER-GIST-301 trial.

Patients with advanced gastrointestinal stromal tumor after receiving fourth-line therapy had extended progression-free survival when given an intra-patient dose escalation of ripretinib to 150 mg twice a day following progression.

A retrospective analysis showed there were more durable survival outcomes with avapritinib versus other tyrosine kinase inhibitors in adult patients with gastrointestinal stromal tumors and a platelet-derived growth factor receptor A D842V mutation

Experts discuss advances in gastrointestinal stromal tumors (GIST) and dive into the evolving landscape and ongoing unmet needs.

Experts discuss KIT and PDGFRα D842V-mutations in GIST and present the NAVIGATOR trial.

Presentation and considerations for a case of PDGFRα D842V-mutated GIST.

A panel of experts review the VOYAGER and INTRIGUE trials.

Key opinion leaders consider later lines of therapy in metastatic KIT exon 9–mutated GIST and how to monitor and mitigate toxicities.

The experts discuss the use of imatinib in patients with KIT exon 9-mutated GIST. Additionally, they comment on surgical options for patients with GIST.

The experts present and discuss a case of a patient with KIT exon 9-mutated GIST, an including an overview of surgical options.

The panelists discuss the phase 3 INVICTUS trial of ripretinib and the phase 1 study of ripretinib intra-patient dose escalation.